Anvisa Clears Five Semaglutide Pens, Ending a Market Standoff
Brazil’s National Health Surveillance Agency (Anvisa) approved five new semaglutide pens on Wednesday, ending weeks of anticipation and multiplying the number of competing products in the country’s booming GLP-1 receptor agonist market. The clearances add to the existing synthetic semaglutide pen from Brazilian drugmaker EMS, whose lower pricing had already forced incumbents to respond. The newly registered medicines include Owozy from Swiss generics giant Sandoz, Seemasun and Orsema from India’s Sun Pharma (the latter via unit Ranbaxy), Zempneo from Brazilian firm Brainfarma, and two further pens whose marketing details are still emerging.
The approvals come four months after Novo Nordisk’s patent exclusivity on semaglutide expired in Brazil, clearing the way for rival synthetic versions that are classified as new medicines rather than biologics. Unlike true generics, these synthetic alternatives are recognized as “novel synthetic medicines” under Brazilian law. The market has become a commercial hotspot: according to data from the national laboratories association Alanac and IQVIA, semaglutide products generated R$5.6 billion in Brazilian pharmacy sales last year. Combined with tirzepatide (Eli Lilly’s Mounjaro), the segment could swell to R$35 billion in the formal market by 2030, Itaú BBA estimates.
Even before today’s announcement, competitive pressures were visible. EMS launched its semaglutide pen at a discount to Novo Nordisk’s Ozempic and Wegovy, triggering special pricing programs from both Novo and its Brazilian distribution partner Eurofarma. Eli Lilly, whose tirzepatide is protected by patents until 2036, surprised analysts by offering combo-purchase discounts—a move that some interpreted as a preemptive response to the growing semaglutide crowd. Anvisa noted that since the Health Ministry prioritized reviews of semaglutide and liraglutide applications, 11 of 24 submissions in the edital have been assessed, resulting in six approvals so far, with more potentially in the pipeline.
What a Six-Player Semaglutide Market Means for Novo Nordisk, EMS, and Newcomers
Novo Nordisk Loses Its Near-Monopoly in Record Time
The Danish drugmaker went from sole semaglutide supplier to facing five new rivals in a matter of months. Even though its branded pens retain strong physician loyalty, the speed of the competitive entry forces Novo and its partner Eurofarma to defend volume with deeper patient-access programs. The existing special pricing arrangements for program patients are now a baseline, not a differentiator. Novo will need to decide whether to sacrifice margin for share or risk losing the newly price-sensitive wave of users identified by Itaú BBA analysts.
Sandoz, Sun Pharma, and Brainfarma Target the Price-Sensitive Bulk
Three distinct strategies are emerging. Sandoz, leveraging its global manufacturing scale, can price Owozy aggressively while tapping Ávita Care’s local distribution. Sun Pharma’s dual-brand play—Seemasun and Orsema—suggests an attempt to cover multiple price points. Brainfarma, as a pure Brazilian generic powerhouse, will likely undercut all international players on a cost-per-pen basis, particularly in public tenders. The net effect: average patient out-of-pocket cost is set to fall substantially, exactly as Itaú BBA predicted when noting that each price reduction “unlocks a wave of users who were previously excluded by cost.”
Eli Lilly’s Surprising Discounts Signal Broader GLP-1 Market Anxiety
Lilly’s decision to offer discounts on tirzepatide combos, despite patent protection until 2036, shows the spillover effect from semaglutide competition. Analysts had expected Lilly to hold prices firm because its dual-acting molecule is seen as clinically superior. Instead, the company appears to be insulating against a scenario where patients choose lower-cost semaglutide options rather than paying a premium for tirzepatide. This preemptive move raises the stakes for Novo Nordisk, which must now defend both its legacy semaglutide and next-generation obesity pipeline against a market that is rapidly commoditizing the first wave of GLP-1s.
Regulatory Tailwinds Could Add More Players
Anvisa’s accelerated review pathway has already concluded 11 of 24 applications for synthetic and biological versions. With six approved and five more already evaluated (likely resulting in a few additional greenlights), the market may expand further before year-end. The availability of synthetic manufacturing techniques, developed since 2022, means barriers to entry are falling fast. For local health systems and private payers, the shift opens a window to negotiate volume-based agreements that could bring GLP-1 therapy within reach of a much larger patient population.
Strategic Moves for Drugmakers and Investors Following the Approval Wave
Executives at Novo Nordisk, Eurofarma, and new entrants should prepare for a market structure where semaglutide is treated as a quasi-commodity with price as the primary differentiator. Novo’s next move—whether to launch a direct-to-consumer discount program outside the current support initiatives—will signal its willingness to defend volume at lower margins.
Investors should track monthly IQVIA sell-out data once the new pens reach pharmacies, as the first quarter of multi-player competition will reveal real demand elasticity. A significant volume upswing despite lower per-unit revenue would validate the Itaú BBA thesis and suggest a substantial market expansion rather than a zero-sum share grab.
Pharmacy chains and payers can begin evaluating tender strategies for large-scale semaglutide procurement, particularly with the synthetic versions now categorized as new medicines. Early negotiations with Brainfarma or Sandoz for bulk supply could lock in favorable prices ahead of further approvals.
Distributors like Ávita Care and partners linked to the new entrants should ensure cold-chain logistics are scaled quickly; any stock-outs during the initial launch window will hand share back to the incumbents.
Risk & Opportunity Assessment
| Commercial Risk | High | Novo Nordisk’s Brazilian semaglutide revenue faces immediate erosion as five new competitors, especially low-cost local player Brainfarma, launch. Lilly’s preemptive discounts on tirzepatide add pressure across the category. |
| Competitive Risk | Critical | The number of semaglutide brands has tripled in one day. EMS, Sandoz, Sun Pharma, and Brainfarma are all equipped with aggressive pricing strategies; first-mover loyalty evaporates quickly in cash-pay markets. |
| Regulatory Risk | Low | Anvisa’s accelerated pathway is working as intended. Remaining applications are likely to yield more approvals, but this increases competition rather than creating obstacles. |
| Reputation Risk | Low | None of the approved products have raised safety concerns. The synthetic classification is well-established, and any adverse events would affect the class, not a single brand. |
| Technology Disruption | Low | The synthetic manufacturing route is now well-understood and widely available. The real disruption has already occurred; today’s approvals are the execution of that trend. |
| Commercial Opportunity | Transformational | For Sandoz, Sun Pharma, and Brainfarma, the entry into a R$5.6 billion market with high growth projections and proven demand elasticity represents a once-in-a-decade volume play in the cash-pay obesity segment. |
Comments 0